These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 35278245)
1. Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema. Duckworth EJ; Murugesan N; Li L; Rushbrooke LJ; Lee DK; De Donatis GM; Maetzel A; Yea CM; Hampton SL; Feener EP Clin Exp Allergy; 2022 Sep; 52(9):1059-1070. PubMed ID: 35278245 [TBL] [Abstract][Full Text] [Related]
2. Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II. Joseph K; Tholanikunnel BG; Bygum A; Ghebrehiwet B; Kaplan AP J Allergy Clin Immunol; 2013 Aug; 132(2):470-5. PubMed ID: 23672780 [TBL] [Abstract][Full Text] [Related]
3. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Kaplan AP; Joseph K Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213 [TBL] [Abstract][Full Text] [Related]
4. Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent. Kaplan AP; Joseph K Clin Rev Allergy Immunol; 2016 Oct; 51(2):207-15. PubMed ID: 27273087 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12. Bhattacharjee G; Revenko AS; Crosby JR; May C; Gao D; Zhao C; Monia BP; MacLeod AR Nucleic Acid Ther; 2013 Jun; 23(3):175-87. PubMed ID: 23582057 [TBL] [Abstract][Full Text] [Related]
6. KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results. Maetzel A; Smith MD; Duckworth EJ; Hampton SL; De Donatis GM; Murugesan N; Rushbrooke LJ; Li L; Francombe D; Feener EP; Yea CM J Allergy Clin Immunol; 2022 Jun; 149(6):2034-2042. PubMed ID: 35086692 [TBL] [Abstract][Full Text] [Related]
7. Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema. Davie RL; Edwards HJ; Evans DM; Hodgson ST; Stocks MJ; Smith AJ; Rushbrooke LJ; Pethen SJ; Roe MB; Clark DE; McEwan PA; Hampton SL J Med Chem; 2022 Oct; 65(20):13629-13644. PubMed ID: 36251573 [TBL] [Abstract][Full Text] [Related]
8. Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies. Farkas H; Balla Z Expert Opin Investig Drugs; 2024 Mar; 33(3):191-200. PubMed ID: 38366937 [TBL] [Abstract][Full Text] [Related]
9. The bradykinin-forming cascade and its role in hereditary angioedema. Kaplan AP; Joseph K Ann Allergy Asthma Immunol; 2010 Mar; 104(3):193-204. PubMed ID: 20377108 [TBL] [Abstract][Full Text] [Related]
10. Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade. Busse P; Kaplan A J Allergy Clin Immunol Pract; 2022 Mar; 10(3):716-722. PubMed ID: 34838707 [TBL] [Abstract][Full Text] [Related]
11. A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain. Ivanov I; Matafonov A; Sun MF; Mohammed BM; Cheng Q; Dickeson SK; Kundu S; Verhamme IM; Gruber A; McCrae K; Gailani D Blood; 2019 Mar; 133(10):1152-1163. PubMed ID: 30591525 [TBL] [Abstract][Full Text] [Related]
12. High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency. Suffritti C; Zanichelli A; Maggioni L; Bonanni E; Cugno M; Cicardi M Clin Exp Allergy; 2014 Dec; 44(12):1503-14. PubMed ID: 24552232 [TBL] [Abstract][Full Text] [Related]
13. Biochemistry, molecular genetics, and clinical aspects of hereditary angioedema with and without C1 inhibitor deficiency. Miyata T; Horiuchi T Allergol Int; 2023 Jul; 72(3):375-384. PubMed ID: 37169642 [TBL] [Abstract][Full Text] [Related]
17. Hereditary angioedema: Pathophysiology (HAE type I, HAE type II, and HAE nC1-INH). Wedner HJ Allergy Asthma Proc; 2020 Nov; 41(Suppl 1):S14-S17. PubMed ID: 33109319 [TBL] [Abstract][Full Text] [Related]
18. Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor. Joseph K; Tholanikunnel BG; Kaplan AP J Allergy Clin Immunol; 2009 Jul; 124(1):143-9. PubMed ID: 19342086 [TBL] [Abstract][Full Text] [Related]
19. Hereditary angioedema in childhood: an approach to management. Ebo DG; Verweij MM; De Knop KJ; Hagendorens MM; Bridts CH; De Clerck LS; Stevens WJ Paediatr Drugs; 2010 Aug; 12(4):257-68. PubMed ID: 20593909 [TBL] [Abstract][Full Text] [Related]
20. Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation. Clermont AC; Murugesan N; Edwards HJ; Lee DK; Bayliss NP; Duckworth EJ; Pethen SJ; Hampton SL; Gailani D; Feener EP Front Pharmacol; 2023; 14():1287487. PubMed ID: 38178859 [No Abstract] [Full Text] [Related] [Next] [New Search]